wilate®

von Willebrand Factor/Coagulation Factor VIII Complex (Human)

VIRNA AND FERNANDO ALCANTARA:

For the Alcantaras, the complicated part was getting the correct diagnosis

From the time he started to walk at 9 months, Fernando Alcantara was covered with purple bruises. It would be 6 more years before his severe type 3 von Willebrand disease (VWD) was correctly diagnosed.

Little Fernando had nosebleeds as well as purple bruises on his arms, legs, and forehead. His mother took him to the doctor, but the doctor was not overly concerned.

During a trip to the emergency room that was unrelated to his frequent bruising, Fernando happened to sneeze. His nose began to bleed heavily. The cardiologist realized Fernando's blood was not clotting properly and he ordered additional testing.

Virna was told that Fernando, who was just 5 years old, had type 1 VWD. He was prescribed desmopressin acetate nasal spray and aminocaproic acid, but the regimen did not provide adequate control of his bleeding.

Virna recalls that at age 7, Fernando broke his ankle and had a serious bleed in his knee that led to a 6-day hospitalization. It was this experience that led Fernando to being correctly diagnosed with severe type 3 VWD. The Alcantaras were referred to a hematologist at a Hemophilia Treatment Center.

"We discussed treatment options with our hematologist and we chose wilate®. As soon as we started using wilate®, things began to improve for Fernando. In just a few months the swelling in his knees started to go down. They are normal now."

Fernando began using wilate® as needed. Today, he continues to infuse to maintain his involvement in several sports.

"I saw a huge difference in the things I could do" Fernando says. "I got involved in sports I had never played before, like water polo and skateboarding. And I still play soccer and flag football. I also learned to self-infuse at summer camp."

Virna recalls, "When he was first diagnosed with VWD, I wanted to put him in a bubble. He's the youngest of my 3 children and has always been so active. I tell people he's my 'wild child.' He's a great kid with a big heart. I envision a bright future for him, keeping up with his buddies, graduating high school, and more."

Indications and Usage

wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes, and for perioperative management of bleeding. wilate® is not indicated for the treatment of hemophilia A.

Please see enclosed Full Prescribing Information.

Please see other side for Important Safety Information.

wilate®

von Willebrand Factor/Coagulation Factor VIII Complex (Human)

The Simple Solution to a Complicated Disease

- Developed specifically for the treatment of VWD[1,2]
- Formulated to provide a physiologic 1:1 ratio of VWF and factor VIII[3,4]
- High purity[2,3]
  - May help reduce the risk of side effects
- Proven efficacy for surgery in all types of VWD[3]
- Dual viral inactivation using a solvent/detergent and PermaHeat treatment[2,3]



Important Safety Information

wilate® is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions to human plasma-derived products, any ingredient in the formulation, or components of the container. wilate® is made from human plasma and carries the risk of transmitting infectious agents.

The most serious adverse reactions to treatment with wilate® in patients with VWD were hypersensitivity reactions. The most common adverse reactions (≥1%) in patients with VWD were hypersensitivity reactions, urticaria, and dizziness. Seroconversions for antibodies to parvovirus B19 not accompanied by clinical signs of disease have been observed. Monitor plasma levels of FVIII activity to avoid sustained excessive FVIII levels, which may increase the risk of thromboembolic events. Development of neutralizing antibodies to FVIII and to VWF, especially in VWD type 3 patients, may occur.

Please see enclosed Full Prescribing Information.

References: 1. Kessler et al. Thromb Haemost. 2011;106:279-288. 2. Stadler et al. Biologicals. 2006;34:281-288. 3. wliate® full prescribing information. Hoboken, NJ: Octapharma; rev 2015. 4. Berntorp et al. Eur J Haematol. 1988;40:205-214.

Date of preparation: 8/2017. WIL-0128-COT

octapharma®

For the safe and optimal use of human proteins